Efficacy of the neurokinin‐1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin‐based chemotherapy

201668 citationsJournal Articlehybrid Open Access

Authors

Paul J. Hesketh

Ian D. Schnadig · Compass Oncology

Lee S. Schwartzberg · Campbell Clinic

Manuel Modiano · Arizona Oncology

Karin Jordan · Martin Luther University Halle-Wittenberg

Sujata Arora · Tesaro (United States)

Dan Powers · Tesaro (United States)

Abstract

Rolapitant provided superior CINV protection to patients receiving carboplatin-based chemotherapy in comparison with the control. These results support rolapitant use as part of the antiemetic regimen in carboplatin-treated patients. Cancer 2016;122:2418-2425. © 2016 American Cancer Society.

Topics & Keywords

Nausea and vomiting management Anesthesia and Pain Management Intraoperative Neuromonitoring and Anesthetic Effects

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Cancer

Volume 122, Issue 15, pp. 2418-2425

DOI: 10.1002/cncr.30054

Field-Weighted Citation Impact: 11.92